BPC-157

Mechanism of Action

BPC-157 (Body Protective Compound-157) is a synthetic pentadecapeptide derived from a partial sequence of a 98-amino-acid protein isolated from human gastric juice. The parent protein, BPC, was first described by the group of Predrag Sikirić at the University of Zagreb, where the majority of published work on this compound originates. BPC-157 itself corresponds to residues 4–18 of the parent glycoprotein and carries the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.

The compound's most consistently described molecular action involves modulation of the nitric oxide (NO) system. Animal model data from the Sikirić laboratory and collaborating groups indicates that BPC-157 can upregulate endothelial nitric oxide synthase (eNOS) expression and stabilize NO production in vascular and connective tissues. This interaction with the NO-cGMP signaling axis is thought to underlie several of the compound's reported vascular and cytoprotective effects, including its apparent gastroprotective activity in NSAID- and alcohol-induced gastric injury models. Administration of non-selective NOS inhibitors such as L-NAME partially attenuates BPC-157's effects in some models, lending support to the NO-dependency hypothesis, though the compound retains partial activity even under NOS blockade, suggesting additional independent pathways are engaged.

A second well-documented mechanism involves the upregulation of early growth response protein 1 (EGR-1), a zinc-finger transcription factor encoded by the EGR1 gene. EGR-1 regulates the transcription of a broad set of growth and repair genes including platelet-derived growth factor (PDGF), fibroblast growth factor (FGF2), and vascular endothelial growth factor (VEGF). In tendon fibroblast cultures and in vivo tendon injury models, BPC-157 administration is associated with elevated EGR-1 expression, which in turn appears to drive downstream VEGFR2 (encoded by KDR) signaling and angiogenic remodeling. This angiogenic component — the formation of new capillary beds within injured tissue — is thought to accelerate nutrient delivery and cellular infiltration at repair sites. The VEGFR2 axis also interacts with focal adhesion kinase (FAK) signaling, which connects extracellular matrix adhesion proteins to intracellular cytoskeletal rearrangement through the paxillin scaffold.

The FAK-paxillin signaling pathway represents a third reported mechanism of action. FAK (focal adhesion kinase, encoded by PTK2) is a non-receptor tyrosine kinase that is activated when integrins engage extracellular matrix components. Studies from the Zagreb group report that BPC-157 stimulates FAK phosphorylation and downstream paxillin activation in fibroblasts, promoting cell motility and directed migration toward injury sites. This is mechanistically consistent with the accelerated wound-closure and tendon-healing phenotypes observed in rodent models. Whether this FAK-paxillin activation occurs through direct receptor binding by BPC-157 or through secondary mediators (such as NO or EGR-1-driven growth factors) remains to be established.

A fourth area of mechanistic investigation involves the growth hormone receptor (GHR) axis. Some published studies from the Zagreb group report that BPC-157 upregulates GHR expression in fibroblasts and in gastric mucosa, and that the peptide's effects can be partially abrogated in hypophysectomized animals, suggesting at least partial GH-axis dependence. This is notable because it may connect BPC-157's tissue-repair properties to systemic anabolic signaling, though the precise molecular interface between BPC-157 and GHR remains poorly characterized. It should be emphasized that a defined, high-affinity receptor for BPC-157 itself has not been identified and formally characterized in the published literature; the compound's promiscuous activity profile suggests either multiple low-affinity interactions or action through secondary messenger systems rather than a single primary receptor.

Pharmacokinetics

The pharmacokinetics of BPC-157 in humans have not been formally characterized. Available data is limited to rodent models and inference from in vivo efficacy studies.

In rodent studies, BPC-157 administered subcutaneously at doses of 10–100 ng/kg shows biological activity, suggesting either high potency at target sites or efficient tissue distribution. The peptide is composed of 15 amino acids and lacks the protective modifications (PEGylation, albumin binding, cyclization) that extend the half-life of many synthetic peptides, making it subject to rapid degradation by circulating peptidases. Estimated plasma half-life in rodents is short — likely on the order of minutes for the intact peptide in systemic circulation — though active fragment metabolites may contribute to observed effects.

The compound is typically administered subcutaneously or intramuscularly in research settings. Oral administration has been studied in rodent gastrointestinal models, where activity has been observed despite the hostile proteolytic environment of the stomach and small intestine. The mechanism by which an unmodified pentadecapeptide retains bioactivity via oral dosing is not established; proposed explanations include local paracrine effects on mucosal tissue prior to full degradation, or the presence of structurally related bioactive fragments. Intraperitoneal administration has been used extensively in rodent studies and shows consistent activity.

Distribution data in rodents suggests the compound reaches multiple tissue compartments including gastrointestinal mucosa, tendon, muscle, liver, and central nervous system. Whether BPC-157 crosses the intact blood-brain barrier in physiologically meaningful concentrations remains uncertain. CNS-related effects observed in animal models (including anxiolysis, anti-seizure activity, and dopaminergic modulation) may occur through peripheral mechanisms or via circumventricular organ access rather than direct BBB penetration.

Elimination is presumed to occur primarily through proteolytic degradation to constituent amino acids, with renal clearance of small peptide fragments. No formal clearance studies in humans exist.

Reported Effects

Primary Research Findings

• Tendon and ligament repair: Sikirić et al. (University of Zagreb, multiple studies 1994–2019) demonstrated accelerated healing of transected rat Achilles tendons with daily BPC-157 administration (10 ng/kg–10 µg/kg, i.p. or SubQ, 14 days). Histological analysis showed improved collagen fiber organization and increased vascularization compared to vehicle controls.
• Gastroprotection: Multiple rodent studies established dose-dependent protection against indomethacin-, aspirin-, and alcohol-induced gastric mucosal lesions. Doses as low as 10 ng/kg (i.p.) produced statistically significant reductions in lesion index in rat models. Protection was observed both prophylactically and therapeutically.
• Inflammatory bowel disease models: In rat models of experimentally induced colitis (acetic acid, TNBS), BPC-157 reduced macroscopic and histological damage scores and normalized several inflammatory markers including TNF-α and IL-6.
• Peripheral nerve regeneration: In sciatic nerve crush and transection models in rats, BPC-157 treatment (10 µg/kg/day) improved functional recovery scores, nerve conduction velocity, and histological measures of axonal regeneration compared to untreated controls.
• Muscle injury: Studies in rat models of muscle crush injury demonstrated faster force recovery and reduced fibrotic deposition with BPC-157 versus vehicle controls.
• Bone healing: Limited data from rat long-bone fracture models suggest accelerated callus formation and mineralization at 10 µg/kg/day.
• Hepatoprotection: In rodent models of hepatotoxicity induced by carbon tetrachloride and paracetamol, BPC-157 reduced serum transaminase elevations and attenuated histological hepatocellular injury.

Secondary / Emerging Findings

• Neuropsychiatric effects: A series of rat behavioral studies from the Zagreb group report anxiolytic-like effects in the elevated plus maze, anti-depressant-like activity in the forced swim test, and attenuation of dopaminergic and serotonergic dysregulation induced by neuroleptic overdose or neurotoxin administration. These findings are intriguing but require independent replication.
• Cardiovascular effects: Animal models of fistula creation, venous occlusion, and heart failure have yielded data suggesting BPC-157 may support collateral vessel formation and cardioprotection in ischemic settings. Mechanistic detail remains limited.
• Corneal and ocular healing: Topical and systemic BPC-157 has been reported to accelerate corneal epithelial re-epithelialization in rabbit scratch models.
• Anti-nociceptive activity: Some animal models suggest analgesic-like properties in neuropathic and inflammatory pain paradigms, potentially via NO-mediated or opioid-interacting pathways.

Effects Not Yet Demonstrated in Humans

All of the above findings are derived from animal models — predominantly rats and, to a lesser extent, mice. As of early 2026, no human clinical trials for BPC-157 have been registered with the FDA, EMA, or equivalent regulatory body. No Phase I pharmacokinetic study, no controlled efficacy trial, and no formal toxicology program in humans exists in the published literature. The translation of rodent pre-clinical findings to human physiology is inherently uncertain for any compound, and particularly so for a peptide whose receptor has not been formally identified.

Community-reported human experiences are available in various online forums and are often cited as anecdotal support for the compound's efficacy. These accounts are not controlled observations, are subject to substantial placebo confounding, and cannot be used to draw conclusions about safety or efficacy in humans.

Dosing & Administration

Research literature (rodent models): Doses in published studies range from 10 ng/kg to 10 µg/kg administered intraperitoneally or subcutaneously, typically once or twice daily for 7–14 days. Notably, efficacy is reported across a very wide dose range (approximately 5 orders of magnitude), which is unusual and not fully explained.

Community practice: Human self-experimental dosing reported in online communities typically falls in the range of 250–500 mcg per day administered subcutaneously or intramuscularly. Some individuals report oral administration at similar or higher doses. These doses are empirically derived and have no direct basis in controlled human data.

Route considerations: SubQ injection into the periumbilical region is the most commonly described route in research-adjacent communities, as it may be relevant for gastrointestinal applications given potential local drainage. IM injection into muscle adjacent to the target tissue is reported for musculoskeletal applications. Oral dosing has been studied in rodent GI models but systemic bioavailability via oral route in humans is unknown and likely low for the intact peptide.

Timing and cycling: The research literature does not establish optimal dosing intervals, cycling protocols, or duration limits. There is no human data to inform duration of use, and no washout period has been empirically characterized.

Peptide quality: BPC-157 is commercially available as a research peptide from numerous suppliers with variable quality control practices. Third-party HPLC analysis and mass spectrometry verification of peptide identity and purity is strongly advised for any research application, as the market includes substantial misrepresented or under-dosed material.

Side Effects & Safety Profile

Commonly Observed

In the rodent literature, BPC-157 is consistently described as non-toxic at doses studied, with no reported dose-limiting toxicity across the dose ranges examined. Injection site reactions (mild edema, transient erythema) represent the only consistently noted local adverse events in animal studies.

In community self-reports, mild injection site reactions are the most frequently mentioned adverse event. Transient warmth, mild soreness, and occasional flushing in the minutes following injection are described. These are consistent with what would be expected from any SubQ peptide injection and do not appear specific to BPC-157's pharmacology.

Less Common

Nausea following injection has been reported anecdotally by some human self-experimenters and may reflect either the compound's GI activity, injection technique, or vehicle-related effects. Some individuals report paradoxical increases in GI discomfort, which could reflect a temporary motility effect given BPC-157's documented activity on the enteric nervous system.

Contraindications & Warnings

The most significant safety concern for BPC-157 is not a demonstrated toxicity but the complete absence of human safety data. Without a formal Phase I dose-escalation trial, the maximum tolerated dose in humans, the pharmacokinetic profile, the safety of extended use, and the potential for idiosyncratic reactions are entirely unknown.

The compound's ability to promote angiogenesis and upregulate growth factors including VEGF raises a theoretical concern in individuals with pre-existing malignancies or high cancer risk, as pathological angiogenesis is a recognized mechanism of tumor growth and metastasis. This concern is theoretical and has not been demonstrated in available animal studies — some authors note that BPC-157 exhibits selective effects on physiological rather than tumor vasculature — but prudence is warranted.

BPC-157's interaction profile with pharmaceutical drugs is essentially unknown. Given documented interactions with the NO system, potential interactions with organic nitrates, PDE5 inhibitors, and antihypertensive agents should be considered. The compound's apparent modulatory effects on dopaminergic and serotonergic systems raise theoretical concern for additive or antagonistic effects with psychiatric medications.

Source quality is a genuine safety consideration given the research peptide market. Impurities, incorrect peptide sequences, bacterial endotoxin contamination, and incorrect dosing concentrations are real risks with unregulated suppliers.

Clinical Evidence

The published literature on BPC-157 is substantial by pre-clinical standards: as of early 2026, the PubMed-indexed literature contains over 150 primary research articles, the large majority from Predrag Sikirić's group at the University of Zagreb School of Medicine. This constitutes a concentrated body of data from a single laboratory, which is both a strength (methodological consistency) and a weakness (lack of independent replication).

Key published work includes:

• Sikirić et al., J Physiol Paris, 1993: Early characterization of gastroprotective effects of the BPC fragment.
• Sikirić et al., Life Sci, 1994: Description of the pentadecapeptide sequence and initial injury model data.
• Multiple Achilles tendon transection studies (Sikirić group, 1999–2015) demonstrating histological and functional improvements in rat tendon repair with BPC-157 vs. vehicle.
• Sciatic nerve crush studies (Šebečić et al., Sikirić group, 2000s) showing recovery improvements in functional, electrophysiological, and histological endpoints.
• Gastrointestinal studies showing protection against NSAID-induced damage (Sikirić group, across multiple publications 1993–2020).

Independent replication is limited but not entirely absent. A small number of groups outside Zagreb have published confirmatory findings in specific models. However, the density of independent replication does not yet match what would be expected for a compound with this breadth of claimed activity.

Evidence grade: B+ — Strong, internally consistent pre-clinical dataset from a prolific research group; significant breadth of studied tissue types; zero human clinical trial data. The grade reflects the quality of existing animal data, not human evidence.

Interaction Considerations

Given the absence of human pharmacokinetic and pharmacodynamic data, interaction predictions for BPC-157 are necessarily speculative. The following considerations arise from its reported mechanisms:

Nitric oxide pathway agents: BPC-157 upregulates eNOS and the NO-cGMP system. Concomitant use with organic nitrates (nitroglycerin, isosorbide mononitrate), PDE5 inhibitors (sildenafil, tadalafil), or other NO donors could theoretically produce additive vasodilatory effects. This remains unstudied.

NSAIDs and anti-inflammatory drugs: BPC-157 has been studied as a protectant against NSAID-induced GI injury in animal models. Whether co-administration with NSAIDs affects efficacy or produces unexpected interactions in humans is not established.

Growth factors and anabolic peptides: Given BPC-157's reported effects on VEGF, EGR-1, and GHR expression, co-administration with exogenous growth hormone, IGF-1, or other angiogenic agents may produce additive effects on tissue growth signaling. This has not been studied and the implications are unknown.

CNS-active medications: Rodent data suggesting modulation of dopaminergic and serotonergic systems implies potential interaction with antipsychotics, SSRIs, MAOIs, and dopaminergic agents. The directionality and clinical relevance in humans are unknown.

CJC-1295 / Ipamorelin: No interaction data exists. Co-administration is practiced in research communities as a "tissue repair plus GH axis" stack, but synergy or interference has not been characterized.

Discovery & Research Timeline

• 1991: Sikirić and colleagues at the University of Zagreb identify BPC-157 as a biologically active 15-amino-acid fragment (positions 4–18) of the larger body protection compound glycoprotein found in human gastric juice. The parent compound had been partially characterized in earlier work examining cytoprotective substances in gastric secretion.
• 1993–1994: Initial publications characterizing gastroprotective properties in rodent ulcer models. The peptide demonstrates protection against ethanol-, HCl-, and NSAID-induced gastric mucosal injury at nanogram-per-kilogram doses.
• 1994–1999: Research expands to systemic tissue protection. Studies examine wound healing, liver protection, and early tendon injury models. The Zagreb group establishes a research program that will produce the majority of the published literature over the following two decades.
• Early 2000s: Tendon and ligament healing studies establish a detailed picture of the compound's effects in musculoskeletal injury models. Achilles tendon transection, medial collateral ligament rupture, and quadriceps tendon avulsion studies are published.
• 2000s–2010s: Research expands to peripheral and central nervous system models. Sciatic nerve crush, spinal cord injury, and traumatic brain injury studies are published. Behavioral studies examining dopaminergic system modulation and anxiolytic effects emerge.
• 2010s: Growing interest in BPC-157 within online research and biohacking communities leads to widespread self-experimental use. No pharmaceutical company undertakes formal drug development. The research peptide market grows substantially.
• 2013: The Zagreb group characterizes FAK-paxillin pathway involvement in BPC-157's wound-healing effects.
• 2016–2019: Cardiovascular and neurological model studies multiply. The compound gains recognition in sports medicine and recovery contexts despite the complete absence of human data.
• 2020–present: Continued pre-clinical publication output from the Zagreb group. No human clinical trials registered. FDA and other regulatory agencies have not approved BPC-157 for any indication. Increased regulatory scrutiny of research peptide markets in the United States and European Union.

Research Disclaimer

BPC-157 has not been approved by the FDA, EMA, or any equivalent regulatory agency for use in humans for any indication. All efficacy data described in this article derives from animal studies, primarily conducted in rodent models. The relevance of these findings to human physiology has not been established in controlled clinical trials.

This article is intended for educational and research purposes only. The information presented does not constitute medical advice, and nothing here should be interpreted as a recommendation to use BPC-157 in humans. Peptides purchased from research suppliers are not manufactured under pharmaceutical-grade GMP conditions and are not intended for human consumption under regulatory frameworks applicable in most jurisdictions.

Individuals considering any experimental compound should consult a licensed medical professional. The risks of self-administering uncharacterized peptides of variable purity and potency are non-trivial and include, but are not limited to, injection site infection, allergic reaction, endotoxin exposure, and unknown systemic effects.

The evidence grade of B+ assigned on this platform reflects the quality and consistency of the pre-clinical dataset relative to other compounds in this space — it does not imply suitability for human use or equivalence to clinical evidence.

Community Research Notes

The following testimonials are drawn from r/Peptides and r/Biohackers. Individual experiences vary. Nothing here constitutes medical advice.

"The first time in months I felt like my body was actually trying to fix itself." — r/Peptides user (partially torn Achilles tendon, avoided surgery after several weeks of consistent use)

"The constant ache that was always there just started fading." — r/Biohackers user (elbow tendinopathy, significant improvement after six weeks)

"Combined BPC-157 with GHK-Cu and deep dermastamping for facial scar reduction — the most effective scar treatment I had tried." — r/Biohackers user

Frequently Asked Questions

Is BPC-157 legal? BPC-157 is not approved by the FDA for human use. It is sold as a research compound. It is not classified as a controlled substance in most countries.

How long does BPC-157 take to work? Most research protocols run 4 to 8 weeks. Some acute injuries show improvement within the first two weeks. Chronic conditions typically need longer cycles.

Does BPC-157 have side effects? In the available research and anecdotal reports, BPC-157 has a remarkably clean side effect profile. Some users report mild nausea or headache, particularly at higher doses. There are no known serious adverse effects from research use.

What is the difference between BPC-157 and TB-500? BPC-157 is stronger for localized healing, particularly tendons and gut tissue. TB-500 is better for systemic inflammation and broader tissue repair. They complement each other, which is why they are often stacked.

Can BPC-157 help with gut issues specifically? Yes. Gut healing is the original research application for BPC-157. It has shown strong results in healing gastric ulcers, protecting intestinal lining, and reducing inflammation in the digestive tract.

Compounds That Pair Well

• TB-500 — A broader regenerative stack; the combination is known as the Wolverine Stack. BPC-157 handles localized tissue repair while TB-500 covers systemic inflammation and wider tissue remodelling.
• KPV — Adds anti-inflammatory and gut healing support alongside BPC-157's established gastroprotective effects.
• GHK-Cu — Combined wound healing and skin repair. Applied topically while BPC-157 is used systemically, this covers both local and systemic healing simultaneously.
• MOTS-c — Maintains energy and endurance during a recovery period when training volume is necessarily reduced.

Build Your Personalised Protocol

BPC-157 is one of many compounds available in the BioStack Generator. Use our research-backed tool to explore potential synergies and build a personalised protocol.

Get Your BioStack →